LIMINATUS PHARMA INC-CL A
LIMNNASDAQTrading Snapshot
- Day Range
- $3.82 – $3.91
- 52-Week Range
- $3.29 – $141.50
- Volume
- $3.02B
- Avg Volume
- $3.01B
- Shares Outstanding
- 1.3M
- Next Earnings
- Nov 12, 2026
Fundamentals Snapshot
- Annual Revenue
- $323,975
- Last Q Revenue
- $78,145
- P/E Ratio
- -0.2
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-26.36
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +235.8%
Why Investors Own LIMN
- ✓High-growth profile — revenue up -3.2% YoY with expanding US Equity exposure.
- ✓Healthy economics — 27% gross margin and 21% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
LIMINATUS PHARMA INC-CL A
LIMN
StockOtter · stockotter.spaceAbout LIMINATUS PHARMA INC-CL A
Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Liminatus Pharma Regains Compliance with Nasdaq Minimum Bid Price Rule
FULLERTON, Calif., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that the Company has regained compliance with Nasdaq's minimum bid price rule.
Liminatus Pharma Engages Synex as Contract Research Organization to Support Phase 1/2a Clinical Development of CD19xCD22 bivalent CAR-T therapy
FULLERTON, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”), a biotechnology company developing innovative cancer therapies, today announced that it has engag
Liminatus Pharma, Inc. Announces Reverse Stock Split of its Common Stock
FULLERTON, Calif., Aug. 18, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”) today announced that its board of directors has adopted resolutions approving a reverse stock spli
Liminatus Pharma Announces Transfer to Nasdaq Capital Market and Extension to Regain Compliance with Minimum Bid Price Requirement
FULLERTON, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) (“Liminatus” or the “Company”), a biopharmaceutical company developing novel therapies for cancer and other serious diseases, tod
Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline
FULLERTON, Calif., June 30, 2026 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (Nasdaq: LIMN) ("Liminatus" or the "Company"), a biotechnology company developing innovative cancer therapies, today announced that it has amend